Traditionally, the presence of tumor-infiltrating lymphocytes (TILs) has been used as an indicator of immune interaction with tumors, with TILs correlating with improved overall survival, particularly in basal-like and HER-2 enriched subtypes [2,3,4]. This evidence concerns the gene ERBB2 and neoplasm.